Literature DB >> 26108797

Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.

Joseph A Caruso1,2,3, Cansu Karakas4,5, Jing Zhang6, Min Yi7, Constance Albarracin8, Aysegul Sahin9, Melissa Bondy10, Jinsong Liu11,12, Kelly K Hunt13, Khandan Keyomarsi14,15,16.   

Abstract

Entities:  

Year:  2015        PMID: 26108797      PMCID: PMC4480452          DOI: 10.1186/s13058-015-0572-5

Source DB:  PubMed          Journal:  Breast Cancer Res        ISSN: 1465-5411            Impact factor:   6.466


× No keyword cloud information.

Erratum

During the editorial process preceding the publication of this article an error was introduced in the heading of “Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients.” This error was only noticed after publication of the final version. Specifically, both data-containing columns are labeled “Elafin Negative.” The data-containing column on the right should in fact be labeled “Elafin Positive (n = 482).” The corrected version can be found here (Table 1). Table 1 has also been updated in the original article to reflect the correct labeling of the columns.
Table 1

Univariate and multivariate analysis of elafin-positive cells in breast cancer patients

A. Univariate analysis, breast cancer (n = 793)
Factors Elafin negative (n = 311) Elafin positive (n = 482) p-value
Age of diagnosis, year 0.02
  Mean55.553.5
  Median (range)55 (26–86)52 (25–87)
Stage <0.0001
  I120 (38.7)115 (24.0)
  IIA128 (41.3)241 (50.2)
  IIB62 (20.0)124 (25.8)
  Unknown12
ER <0.0001
  Positive266 (85.5)280 (58.3)
  Negative45 (14.5)200 (41.7)
  Unknown02
PR <0.0001
  Positive218 (70.1)236 (49.2)
  Negative93 (29.9)244 (50.8)
  Unknown02
HER-2 0.013
  Positive42 (13.5)98 (20.4)
  Negative269 (86.5)383 (79.6)
  Unknown01
Grade <0.0001
  I41 (14.2)31 (6.8)
  II186 (64.6)197 (43.5)
  III61 (21.2)225 (49.7)
  Unknown2329
Tumor subtype <0.0001
  Luminal A185 (61.9)158 (33.1)
  Luminal B45 (15.1)94 (19.8)
  Her2 positive42 (14.0)98 (20.7)
  Triple negative27 (9.0)125 (26.4)
  Unknown127
Recurrence <0.0001
  No250 (80.9)298 (62.3)
  Yes59 (19.1)180 (37.7)
  Unknown24
B. Multivariate Cox proportional hazards analysis of clinicopathologic variables’ influence on breast cancer RFS in whole cohort (n = 793)
Factor HR Se P 95% CI
Stage
  Ireferent
  IIA1.670.310.0051.17-2.39
  IIB2.410.47<0.00011.65-3.52
Age 0.980.01<0.00010.97-0.99
Elafin Positive 1.940.3<0.00011.44-2.62
Univariate and multivariate analysis of elafin-positive cells in breast cancer patients
  1 in total

1.  Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.

Authors:  Joseph A Caruso; Cansu Karakas; Jing Zhang; Min Yi; Constance Albarracin; Aysegul Sahin; Melissa Bondy; Jinsong Liu; Kelly K Hunt; Khandan Keyomarsi
Journal:  Breast Cancer Res       Date:  2014       Impact factor: 6.466

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.